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Abstract
Background: Ataxia telangiectasia-mutated and Rad3-related (ATR) is a member of the PIK-related family which plays,
along with ATM, a central role in cell-cycle regulation. ATR has been shown to phosphorylate several tumor suppressors
like BRCA1, CHEK1 and TP53. ATR appears as a good candidate breast cancer susceptibility gene and the current study
was designed to screen for ATR germline mutations potentially involved in breast cancer predisposition.
Methods: ATR direct sequencing was performed using a fluorescent method while widely available programs were used
for linkage disequilibrium (LD), haplotype analyses, and tagging SNP (tSNP) identification. Expression analyses were
carried out using real-time PCR.
Results: The complete sequence of all exons and flanking intronic sequences were analyzed in DNA samples from 54
individuals affected with breast cancer from non-BRCA1/2 high-risk French Canadian breast/ovarian families. Although
no germline mutation has been identified in the coding region, we identified 41 sequence variants, including 16 coding
variants, 3 of which are not reported in public databases. SNP haplotypes were established and tSNPs were identified in
73 healthy unrelated French Canadians, providing a valuable tool for further association studies involving the ATR gene,
using large cohorts. Our analyses led to the identification of two novel alternative splice transcripts. In contrast to the
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transcript generated by an alternative splicing site in the intron 41, the one resulting from a deletion of 121 nucleotides
in exon 33 is widely expressed, at significant but relatively low levels, in both normal and tumoral cells including normal
breast and ovarian tissue.
Conclusion: Although no deleterious mutations were identified in the ATR  gene, the current study provides an
haplotype analysis of the ATR gene polymorphisms, which allowed the identification of a set of SNPs that could be used
as tSNPs for large-scale association studies. In addition, our study led to the characterization of a novel ∆33 splice form,
which could generate a putative truncated protein lacking several functional domains. Additional studies in large cohorts
and other populations will be needed to further evaluate if common and/or rare ATR sequence variants can be associated
with a modest or intermediate breast cancer risk.
Background
All common cancers show some degree of familial cluster-
ing [1]. Most of the familial aggregation, especially in
breast cancer [2], results predominantly from inherited
susceptibility [3]. Linkage studies in the 1990s led to the
discovery of several predisposition genes associated with
many rare familial cancer syndromes, thus providing fun-
damental insights into various pathways of carcinogenesis
[4]. Nevertheless, this approach has mainly been limited
to genes with relatively rare, highly penetrant alleles, for
several reasons, such as a lack of power to detect alleles
conferring modest or moderate risks that are believed to
be involved in common cancers [1,5-7]. Analyses of risk
attributable to such alleles in the known breast cancer sus-
ceptibility genes (e.g. BRCA1, BRCA2, TP53, PTEN, ATM)
suggest they are responsible for ~25% of the familial com-
ponent of breast cancer risk [6,8,9]. The number and
properties of genetic variants that account for the remain-
ing 75% of inherited risk are largely unknown. It has been
proposed that a complex polygenic model is the best
explanation for this missing genetic risk [10,11] and per-
haps the majority of breast cancers arise in a susceptible
minority of women [2,12].
Under the Common Variant/Common Disease (CV/CD)
model, disease susceptibility is suggested to result from
the joint action of several common variants, with unre-
lated affected individuals sharing a substantial proportion
of disease alleles [13-15]. The alternative is the heteroge-
neity hypothesis, which maintains that genetic suscepti-
bility to common disease is caused by many different rare
genetic variants, with a relatively large effect produced by
each allele [16-19]. If most cancer susceptibility is related
to fundamental processes of cellular control, rare alleles
might turn out to be the more important component and
should be detectable by linkage analysis and/or the candi-
date gene re-sequencing approach [5,6].
The central role of BRCA1  and  BRCA2  genes in DNA
repair, recombination, cell cycle control and transcription
[20,21] has led to the investigation of the implication of
several similarly acting genes in breast and/or ovarian can-
cer predisposition, including ATM (Ataxia telangiectasia-
mutated) [22-27], CHEK2 [28,29], TP53 [30], PTEN [31],
STK11 [32] and a few other genes involved in DNA repair
[33]. Ataxia-telangiectasia-mutated and Rad3-related
(ATR) is a member of the phosphatidyl inositol-kinase
(PIK)-related family which plays, along with ATM, a cen-
tral role in cell-cycle regulation, by transducing DNA dam-
age signals to downstream effectors of cell-cycle
progression [34]. In response to double-strand breakage,
stalled replication forks or DNA adducts, ATR complexed
with ATR-interacting protein (ATRIP) is recruited and
then phosphorylates a number of proteins involved in
DNA damage, including H2AX, 53BP, TP53, NBS1 and
CHEK1 [35-38], thereby activating cell checkpoints, DNA
repair or apoptosis. ATR is also able to bind to Rad17 and
BRCA1 and to associate with components of the nucleo-
some remodeling and deacetylating complex [39-41]. Fur-
thermore, ATR has recently been shown to interact with
the Fanconi Anemia complex [42], which growing
number of evidences link to the two BRCA genes [[21], for
review see [43]]. A recent study has also demonstrated
that the Mre11/Rad50/NBS1 (MRN) complex, a central
component in the cellular response to ionizing radiations
and other causes of double-strand breaks, is required for
ATR-dependant phosphorylation mechanisms of the pro-
tein Smc1 (Structural maintenance of chromosomes 1)
[44]. ATR knockout studies showed that ATR is essential
for somatic cell growth and genomic integrity in the
embryo and that its deletion leads to genomic disruption
and early embryonic lethality in mice [45,46]. Moreover,
it has been reported that disruption of the ATR gene leads
to an increase in the incidence of large benign tumors in
heterozygotes, possibly indicating that deficiency in ATR
affects the rate of tumor initiation [45].
Based on the major role of ATR in cellular response to
DNA damage and its multiple interactions with several
proteins such as BRCA1 [40,47], ATR represents an attrac-
tive candidate gene to potentially explain a fraction of the
remaining breast cancer susceptibility. The current study
was designed to assess the possible involvement of ATR
germline mutations in breast cancer susceptibility. For
this purpose, the complete sequence of the 47 exons and
flanking intronic sequences of the ATR gene were ana-BMC Cancer 2006, 6:230 http://www.biomedcentral.com/1471-2407/6/230
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lyzed in DNA samples from individuals affected with
breast cancer from non-related BRCA1- and BRCA2-nega-
tive high-risk French Canadian breast/ovarian families.
Methods
Ascertainment of families and DNA extraction
The recruitment of high-risk French Canadian breast and/
or ovarian families started in 1996 through a research
project, which thereafter evolved in a large ongoing inter-
disciplinary research program designated INHERIT
BRCAs. More details regarding ascertainment criteria,
experimental and clinical procedures as well as the
INHERIT BRCAs research program have been described
elsewhere [48-52]. A major component was to identify
and characterize BRCA1 and BRCA2 mutations in French
Canadian high-risk families (CGL cohort) [52].
Subsequently, another component was designed for the
"Localization and identification of new breast cancer sus-
ceptibility loci/genes". Ethics approval for this latter study
was also obtained from the different institutions partici-
pating in this research project and each participant know-
ing their inconclusive BRCA1/2 test results status had to
sign a specific informed consent for their participation in
this component. A subset of 54 high-risk French Canadian
breast/ovarian cancer families were recruited in the
present study according to the following ascertainment
criteria 1) three or more breast cancer cases diagnosed
before the age of 65 (48 families), 2) two or more breast
cancer cases (<65) if one breast cancer was diagnosed
before 45 years (5 families), 3) or when there was a strong
family history of breast/ovarian cancer (e.g. daughter-
mother-grand-mother) (1 family). All participants had to
be at least 18 years of age and mentally capable. The diag-
noses of breast and/or ovarian cancer were confirmed by
obtaining a pathology report, and when two or more sub-
jects were available within a family, the youngest subject
was systematically chosen for this study. The mean age at
diagnosis of these 54 subjects affected with breast cancer
was 45.5 years old (30–59 years), while 46 of them have
been diagnosed before 50 year of age and 11 were affected
by more than one breast cancer case. The analysis of the
breast cancer history revealed that 15 (28%), 18 (33%)
and 19 (35%) families included 1–2, 3 or ≥ 4 case(s) in at
most 2nd degree relatives, respectively. When including all
breast cancer cases in the family history occurring in at
most 3rd degree relatives from the index case, 10 (18%),
16 (30%) and 28 (52%) families have 1–2, 3 or ≥ 4
case(s), respectively.
The BRCA1/2 status of each participant was previously
assessed [52]. Briefly, to this day, genomic DNA samples
have been first tested for a panel of 29 mutations, includ-
ing 26 truncating mutations and 3 unclassified variants
(two missense mutations and one in-frame deletion),
observed and/or reported in the French Canadian popula-
tion [52]. Thereafter, DNA samples of individuals
included in this study were sent to Myriad Genetic Labo-
ratories (Salt Lake City, Utah, USA) for full-length BRCA1/
2 sequencing following their Comprehensive BRACAnalysis
®-BRCA1 and BRCA2 gene sequence analysis for susceptibility
to breast and ovarian cancer test, with the exception of 9 sub-
jects for which DNA samples from another affected indi-
vidual of the family (n = 7) or unaffected parents of cancer
cases (n = 2) were sent to Myriad as previously described
[49,50,52]. Evidence of the absence of genomic rearrange-
ments in BRCA1/2 genes was thereafter investigated by
Multiplex Ligation-dependant Probe Amplification
(MLPA) for 45 of the 54 subjects and BRCA1/2 Southern
analysis for 32 of the 54 individuals. For seven of the
remaining subjects, MLPA was performed on another
individual of the family [53], while for two subjects this
analysis was not performed.
Genomic DNA from 73 healthy unrelated French Cana-
dian women was obtained from Dr Damian Labuda at the
Centre de cancérologie Charles Bruneau, Hôpital Ste-Jus-
tine, Montreal, Canada. The individuals who provided
these samples were recruited on a non-nominative basis,
in the framework of long-term studies aiming the charac-
terization of the genetic variability in human populations,
approved by the Institutional Ethic Review Board. DNA
from peripheral blood was isolated by conventional
methods, either phenol-chlorophorm or using Gentra kits
(Minneapolis, MN, USA). The mean age of these individ-
uals was 45.2 years old; 2 (2.7%), 26 (35.6%), 23 (31.5),
17 (23.3%) and 5 (6.8%) of them were between 25–29,
30–39, 40–49, 50–59 and 60–69 year of age, respectively.
The validation group comprised 46 BRCA1/2-negative
breast cancer proband cases of French origin belonging to
multiple-case breast cancer families from the following
sources: high-risk breast cancer only and breast/ovarian
cancer families referred for genetic testing at the Depart-
ment of Preventive Medicine at Creighton University
School of Medicine, Omaha, NE, and at the cancer genetic
counseling unit at Centre Léon Bérard, Lyon, France, and
a population-based study including women diagnosed
with breast cancer below age 46 years, recruited through
the Rhône region cancer registry, France. The cancer status
of index cases was confirmed through pathology reports.
Cancers reported in relatives were verified through pathol-
ogy reports, hospital records and death certificates. Index
cases have been screened for mutations in BRCA1 and
BRCA2 [54,55]. All subjects provided written informed
consent for participation in the study. Approval for the
study was obtained from the International Agency for
Research on Cancer (IARC) ethics committee.BMC Cancer 2006, 6:230 http://www.biomedcentral.com/1471-2407/6/230
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The mean age at diagnosis of these 46 French subjects
affected with breast cancer was 39.7 years old (19–61
years); 44 of them have been diagnosed before 50 year of
age and five were affected by more than one cancer case.
The analysis of the breast cancer history revealed that 23
(50%), 9 (20%) and 14 (30%) families included 1–2, 3 or
≥ 4 case(s) in at most 2nd degree relatives, respectively.
When including all breast cancer cases in the family his-
tory occurring in at most 3rd degree relatives from the
index case, 12 (26%), 14 (31%) and 20 (43%) families
have 1–2, 3 or ≥ 4 case(s), respectively.
PCR amplification, mutation analysis and variant 
characterization
The intron-exon boundaries of the ATR gene were deter-
mined by aligning GenBank mRNA records
(NM_001184) with genomic sequence records
(NC_000003). ATR spans approximately 130 kb and is
composed of 47 exons (3q22-q24: 143650778-
143780349). PCR amplicons using primers designed by
the Primer Express 2.0 software (Applied Biosystems, Fos-
ter City, CA, USA) covered the entire mRNA encoding por-
tions and flanking intronic sequences from genomic
DNA. Forty primer pairs were used to amplify fragments
ranging in size from 351 bp to 1385 bp, which were
sequenced with primers also indicated in the table [see
Additional file 1]. ATR direct sequencing was performed
on an ABI3731 automated sequencer using version 3.1 of
the Big Dye fluorescent method according to the manufac-
turer's instructions (Applied Biosystems, Foster City,
USA). Sequence data were analyzed using the Staden
preGap4 and Gap4 programs.
LD analysis, haplotype estimation and tagging SNP 
selection (tSNP)
To estimate the pattern of linkage disequilibrium (LD), all
41 SNPs identified in our breast cancer case series have
been genotyped. The LDA program [56] was used to cal-
culate pairwise LD for each SNP pair. Lewontin's |D'| was
used as a measure of LD between SNPs [57,58].
Haplotype analysis was performed using PHASE 2.1.1
software [59,60]. This program (PHASE) estimates haplo-
type frequencies with a Bayesian-based algorithm and
then uses a permutation test to determine the significance
of differences in inferred haplotypes between cases and
controls. All association tests were run under default con-
ditions, with 1000 permutations. Haplotype frequencies
were estimated using the SNPs with minor allele fre-
quency (MAF) ≥ 5% identified in both sample series
(cases and controls). Haplotype blocks were identified
using genotyping data from control individuals as well as
using HapMap data from the CEPH cohort [61] using the
Haploview [62,63] software. Tagging SNPs (tSNPs) from
each LD block were then identified using the same soft-
ware. Splice site prediction scores were evaluated using
SSPNN [64] while protein alignment was performed
using ClustalW [65].
RNA isolation from cell lines and normal tissue samples
Total RNA was extracted using TRI Reagent® (Molecular
Research Center inc, Cincinnati, OH, USA) according to
the manufacturer's instructions as previously described
[66] from 1) EBV-transformed B-lymphoblastoid cell
lines from the 54 cases used for our mutation screening;
2) nine cancer cell lines obtained from the American Type
Culture Collection (ATCC) including, two estrogen recep-
tor (ER)-negative breast cancer cell lines (BT-20 and MDA-
MB-231), four ER+ breast cancer cell lines (BT-474,
CAMA-1, MCF7 and ZR75) and three prostate cancer cell
lines (22RV1, LNCaP, PC3); and 3) the HaCat human
skin keratinocyte cell line which was generously supplied
by Dr. N.E. Fusenig (German Cancer Research Center,
Heidelberg, Germany) [67,68]. Total RNA samples from
normal tissues were purchased directly either from Strata-
gene (breast and ovary) (La Jolla, CA, USA), BioChain
Institute Inc. (leukocyte) (Hayward, CA, USA), or Clon-
tech (all other normal tissue samples) (Palo Alto, CA,
USA). RNA samples were then processed as previously
described [66]. Thereafter, reverse transcription of 2.5 µg
of standardized RNA samples was performed using 250 ng
random hexamers and 200 U of SuperScript™ II RNase H-
Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) fol-
lowing the supplier's protocol.
Characterization of the ∆33 and ins∆Int41 alternative 
splice transcripts
∆33 alternative splice transcript
In order to investigate if the SNP c.5739-4del9+T may lead
to alternative splice transcript(s), a PCR reaction was per-
formed, using the forward primer (5'- GCAGAT-
GGAAAATCTACAACATGGA) and reverse primer (5'-
TGATTTCCATATTGTAGAGATCTGCCA) designed to
allow amplification of a specific ATR  cDNA fragment
spanning nucleotides 5479 to 6348 of the wild-type
mRNA, with cDNA samples from immortalized cell lines
from two homozygous and one heterozygous individuals
for this variant, as well as two wild-type individuals. PCR
product lengths were analyzed by migration on 1.5% aga-
rose gel and sequenced in both orientations. Thereafter
amplified ATR  cDNA fragments were subcloned in the
pCRII vector (TA cloning kit from Invitrogen) according
to the manufacturer's instructions. After growing colonies
and extracting the plasmid DNA samples using the GFX
Micro Plasmid Prep Kit (Amersham), sequencing of each
amplicon was performed as described above using the for-
ward amplification primer. The only alternative splice
transcript observed, designated ∆33, yielded to a 749 bp
PCR product, while the wild-type fragment length was
870 bp.BMC Cancer 2006, 6:230 http://www.biomedcentral.com/1471-2407/6/230
Page 5 of 21
(page number not for citation purposes)
Then, to further investigate for the presence of alternative
splice transcript(s), which could be associated with the
SNP c.5739-4del9+T, a series of primers were designed on
exon-exon junctions to amplify different cDNA fragments
covering exons 30–38 using the same cDNA samples
described above. Four forward primers were designed on
exon junctions 29–30, 30–31, 31–32 and 32–33 (F29-30:
5'-GAACCAGACCAGATCATTCATTA-3', F30-31: 5'-
TAACAGGTCCGAGTGGACAGA-3', F31-32: 5'-CAGCA-
GATGGAAAATCTACAACAT-3', F32-33: 5'-GTGAGATT-
GCACATGTTATGTGAG-3') and five reverse primers were
designed on exon junctions 33–34, 34–35, 35–36, 36–37
and 37–38 (R33-34: 5'-TTGTAATCTGGTCTTTTGTT-
GAGG-3', R34-35: 5'-TGGTGAACATCACCCTTGGAC-3',
R35-36: 5'-CACGCGGTCACATCCTTATATT-3', R36-37:
5'-CCATATTGTAGAGATCTGCCAAAAT-3', R37-38: 5'-
CCAGCTTTTTCCCATTCATAT-3'). Each forward primer
was used in combination with each reverse primer, thus
resulting in twenty distinct overlapping PCR fragments.
Given that the intronic c.5739-4del9+T variant is located
at the splice acceptor site of exon 34, four additional
reverse and forward primers were designed on the puta-
tive ∆33-35 and 33–35 exon junctions to verify if there is
a splice variant resulting specifically from exon 34 skip-
ping (F∆33-35: 5'-CCAGCATTCTCCAGGGTGA-3', F33-
35: 5'-TACTAAGCCTCAACAAAAGGGTGA-3', R∆33-35:
5'-CTGGTGAACATCACCCTGGA-3', R33-35: 5'-GCCT-
GGTGAACATCACCCTTT-3'). PCR reactions were per-
formed for 40 cycles using cDNA samples from c.5739-
4del9+T variant carriers, as well as two wild-type individ-
uals, and analyzed as described above.
ins∆Int41 alternative splice transcript
In order to investigate whether the SNP c.7041+8G/A may
lead to alternative splice transcript(s), a strategy similar to
that described above was used. Two forward primers were
designed on exon junctions 38–39 and 39–40 (F38-39: 5'-
GTCAAAGTCATCTTATCCCATGC-3', F39-40: 5'-AACCG-
GTTGATGGAAGTAGTTCCA-3') and two reverse primers
were designed on exon junctions 43–44 and 44–45 (R43-
44: 5'-CTACTACTGTACCATGATGTAGGATCAG-3', R44-
45: 5'-GTTTCTCCCTTATTGAAAAGACAATTG-3'. Further-
more, two additional reverse and forward primers were
designed specifically on putative exon41-intron41 (For-
ward) and intron41-exon42 (Reverse) junctions to detect
a splice variant in which the exon 41–42 junction could
have been altered (F41-int41: 5'-CAATTCCTTGAT-
TAATAAGGTTG-3', R42-int41: 5'-CTCTGCATCTTTTCT-
TAAGCACTCA-3'). The F41-int41 primer was used in
combination with R43-44 and R44-45 while the R42-
int41 primer was used in combination with F38-39 and
F39-40. PCR reactions were performed for 40 cycles using
cDNA samples from the c.7041+8G/A heterozygote car-
rier, as well as two wild-type individuals and PCR prod-
ucts have been analyzed as described in the previous sub-
section. The structure of the alternative splice variant
(r.[7041_7042ins7041+1_7041+441], designated in the
current study as ins∆Int41, amplified using either F41-
int41 or R42-int41 with appropriate external primers was
confirmed by sequencing subcloned PCR products.
Quantitative RT-PCR (QRT-PCR) for the ∆33 splice 
transcript
Primer and Taqman probe design
Primers and Taqman probes for ATR wild-type and ∆33
splice transcript fragments were designed with the assist-
ance of the Primer Express 2.0 software. The primer and
probe sequences were; ATR wild-type: forward primer: 5'-
AACTGGGTAGCTCGACTAGAAATGA-3', reverse primer:
5'-TTCATTGTAATCTGGTCTTTTGTTGAG-3', probe: 5'-
FAM-TCCGGAGAGCCAGGA-3';  ATR  splice transcript:
forward primer: 5'-GAGGCTCCTACCAACGAGGAT-3',
reverse primer: 5'-TCATTGTAATCTGGTCTGGAGAATG-
3', probe: 5'-FAM-TGGTTTGATGCTATGCTC-3'. All
probes were purchased from Applied Biosystems, as were
primers and probe for 18S RNA, which was used as endog-
enous control gene.
Subcloning and standard curves
cDNA samples prepared from RNA extracted from immor-
talized cell lines were used to amplify by PCR three frag-
ments corresponding to the ATR cDNA region spanning
nucleotides 5748–5858 (NM_001184), the ATR  splice
transcript spanning nucleotides 5626–5857 and includ-
ing a deletion of the last 121 nucleotides of exon 33, and
a fragment spanning nucleotides 450–619 of 18S RNA.
The fragments were thereafter subcloned in the pCR®II
vector (TA Cloning® from Invitrogen, Carlsbad, CA, USA)
according to the manufacturer's instructions. To ensure
amplification specificity, the reverse primer for the wild-
type ATR fragment was designed on the junction between
exons 33–34 while the reverse primer specific to the alter-
nate splicing transcript was placed on the new exon 33–34
junction created by the exon 33 3'-deletion. Plasmid con-
structions were amplified and purified using Plasmid
Maxi Kit (Qiagen, Mississauga, ON, Canada). Specific
standard curves were generated by making 2-fold serial
dilutions of plasmid constructions in the appropriate
range for each quantitation assay.
QRT-PCR assays
QRT-PCR assays were performed in triplicate on an ABI
7900 Sequence Detection System (Applied Biosystems) as
previously described [66]. For all the assays, a reaction
mixture was prepared in a final volume of 10 µl with 1X
Taqman Master Mix Buffer (Applied Biosystems) which
included Taq Gold polymerase, 200 nM of Taqman®
probe, 900 nM of each primer for ATR wild-type and alter-
native transcript assays or 50 nM of each primer for 18SBMC Cancer 2006, 6:230 http://www.biomedcentral.com/1471-2407/6/230
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RNA assays, and cDNA samples reverse-transcribed from
total RNA. The amount of cDNA used for quantitation
was 15 ng for wild-type, 150 ng for splice transcript and
1.5 ng for 18S RNA.
QRT-PCR for the ins∆Int41 splice transcript
cDNA corresponding to 20, 200, 500 ng and 1 µg of total
RNA coming from the immortalized cell lines of the
c.7041+8G/A heterozygote carrier, as well as nine wild-
type individuals, were used to perform fluorescent-based
real-time PCR quantification using the Light Cycler Real-
Time PCR apparatus (Roche Inc, Nutley, NJ). The primer
sequences were; ATR  wild-type: forward primer: 5'-
GTCATATACACTCCCTTTTCTTTA-3', reverse primer: 5'-
GTCATATACACTCCCTTTTCTTTA-3';  ATR  splice tran-
script: forward primer: 5'- ACCATTTACTTTGTCTCCATTA-
3', reverse primer: 5'-GTCATATACACTCCCTTTTCTTTA-
3'. Expression analyses were then carried out as previously
described [69].
Results
ATR mutation analysis and variant characterization
Although no truncating mutation was found in the ATR
coding region of our French Canadian breast cancer cases,
we identified 41 variants in ATR  exonic and flanking
intronic sequences (Table 1). These included 16 nucle-
otide substitutions in the exons, 6 of which resulted in
amino acid changes, and 25 variants in the intronic
regions, consisting of 23 nucleotide substitutions, one
deletion and one insertion-deletion. Of the 41 variants,
21 were novel while 20 were reported in the single nucle-
otide polymorphism (dbSNP) database. Eight of the iden-
tified variants were very common polymorphisms with
MAF around 40%. Of these, three were intronic variants,
one was located in the 3'-UTR region and four were cod-
ing polymorphisms, only one of which caused an amino
acid change. This latter variant, Thr211Met, is located in
exon 4 and was previously reported in the dbSNP data-
base. Twenty-five of the identified variants had MAF
around or below 5% (Table 1). Of these, 14 polymor-
phisms were found exclusively in 3 individuals (s1-3-6-7-
13-16-17-18-19-23-24-31-32-33), and 9 were observed
only once. The six coding variants causing an amino acid
change were genotyped in an independent European Cau-
casian validation group consisting of 46 unrelated breast
cancer cases originating from high-risk non-BRCA1/2
families (Table 2). Frequencies were similar in both
cohorts as well as with frequencies reported in the dbSNP
database. Comparison of most common variants with
those described in the recent study in Finnish families
shows no notable differences in carrier frequency, with
the exception of the c.268C>T variant which has a carrier
frequency of 12.7% in the Finnish families and which was
not observed in our cases [70]. This may be attributed to
population-specific differences.
Genotype and MAF were determined in cases and con-
trols, both of French Canadian origin, for all coding vari-
ants as well as the intronic variants showing a MAF ≥ 5%.
As indicated in Table 3, most genotype distributions sig-
nificantly deviating from those expected under Hardy-
Weinberg Equilibrium (HWE) involved rare SNPs (i.e. s6-
7-13-16-18-32-33) found exclusively in 3 cases who seem
to carry a specific allele.
Conservation of human ATR residues
Among exonic variants resulting in amino acid substitu-
tions, c.6394T>G (Tyr2132Asp) was located in the FAT
(FRAP/ATM/TRRAP) domain and c.7274G>A
(Arg2425Gln) was located in the PI3Kc (phosphoi-
nositide 3-kinase related catalytic) domain (Figure 1)
while the remaining amino acid substitutions were
located outside catalytic domains. Comparison of mis-
sense substitutions was performed across relevant species
in order to obtain a more representative prediction of the
importance of specific residues on protein function.
Alignment of ATR  orthologue sequences illustrated in
Table 4, revealed that, with the exception of Thr211Met
and Val959Met, which are non-conserved residues
(Thr211Met being conserved only in Pan troglodytes and
Canis familiaris), Val316Ile and Lys764Glu are conserved
in Pan troglodytes and in more distant species such as Canis
familiaris, Mus musculus, Xenopus laevis and Fugu rubribes.
Since Val316 and Lys764 residues are invariant from
human to fish, this could suggest that these positions are
under strong functional constraint. Tyr2132 and Arg2425
are only conserved in higher species, namely Pan troglo-
dytes and Canis familiaris, respectively.
LD analysis
A graphical representation of the pairwise LD between all
41 SNPs identified in cases, as measured by Lewontin's
|D'|, is shown in Figure 2. As demonstrated, the majority
of SNPs are in strong LD with each other. Complete LD
was found between the two most distantly separated
intragenic SNPs (SNPs 1 and 41, inter-marker distance
~130 kb, |D'| = 1) which suggested that LD at the ATR
locus did not decrease significantly with distance. For a
few associations involving SNP2, the weaker LD values
range from 0.113 to 0.441. Indeed, the only pair of adja-
cent SNPs displaying weak LD is SNP2 in association with
SNP1 and SNP3 (D' = 0.118 and 0.113, respectively) and
SNP40 with SNP39 (D' = 0.467). The SNP40 also dis-
played a large spectrum of LD values, interestingly all of
these SNPs involved with SNP40, show a MAF >5%.
Haplotype analysis and tSNP identification
To reduce genotyping costs and efforts in future associa-
tion studies, it is useful to identify tSNPs that would rep-
resent the majority of observed haplotypes, but with
minimal reduction in power to detect a possible associa-B
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Table 1: Observed coding and intronic sequence variants and genotype frequencies in familial breast cancer cases
SNP Designation Genotype Frequency
SNP SNP ID1 dbSNP ID Amino acid change Location Common homozygote (expected)2 Heterozygote (expected)2 Rare homozygote (expected)2 MAF
1 c.160-179deIT N/A - Intron 1 0.94 (0.91) 0.02 (0.09) 0.04 (0.00) 0.046
2 c.60-51A>T N/A - Intron 1 0.81 (0.82) 0.19 (0.17) 0.00 (0.01) 0.093
3 c. 293-43G>A N/A - Intron 3 0.94 (0.90) 0.02 (0.10) 0.04 (0.00) 0.049
4 c. 293-19C>T N/A - Intron 3 0.94 (0.94) 0.06 (0.06) 0.00 (0.00) 0.029
5* c.632C>T rs2227928 Thr211Met Exon 4 0.42 (0.38) 0.38 (0.47) 0.19 (0.15) 0.385
6 c. 946G>A rs28897764 Va131611e Exon 4 0.94 (0.90) 0.02 (0.10) 0.04 (0.00) 0.047
7 c. 1326A>G rs28897765 Lys442Lys Exon 5 0.94 (0.91) 0.02 (0.09) 0.04 (0.00) 0.046
8 c. 1488C>T N/A Val496Val Exon 6 0.98 (0.98) 0.02 (0.02) 0.00 (0.00) 0.010
9 c. 1732+I66A>G N/A - Intron 7 0.98 (0.98) 0.02 (0.02) 0.00 (0.00) 0.009
10 c. 1732+279A>G N/A - Intorn 7 0.94 (0.94) 0.06 (0.06) 0.00 (0.00) 0.028
11 c. 1776A>T rs2227930 Gly592Gly Exon 8 0.40 (0.34) 0.38 (0.49) 0.23 (0.17) 0.415
12 c. 1815T>C rs2227929 Asp605Asp Exon 8 0.40 (0.35) 0.40 (0.48) 0.21 (0.17) 0.406
13 c. 1950G>A rs28910270 Glu650Glu Exon 9 0.94 (0.91) 0.02 (0.09) 0.04 (0.00) 0.047
14 c.2290A>G N/A Lys764Glu Exon 10 0.98 (0.98) 0.02 (0.10) 0.00 (0.00) 0.010
15 c. 2634-74T>C rs9869842 - Inton 12 0.39 (0.34) 0.39 (0.49) 0.22 (0.17) 0.417
16 c. 2875G>A rs28910271 Val959Met Exon 14 0.94 (0.90) 0.02 (0.10) 0.04 (0.00) 0.052
17 c. 2977-97T>C N/A - Intron 14 0.94 (0.91) 0.02 (0.09) 0.04 (0.00) 0.048
18 c. 3120G>A rs28910272 Leu1040Leu Exon 15 0.94 (0.91) 0.02 (0.09) 0.04 (0.00) 0.048
19 c.3172-26T>A N/A - Intron 15 0.94 (0.91) 0.02 10.09) 0.04 (0.00) 0.046
20 c.3357+128G>A rs13091637 - Intron 16 0.50 (0.51) 0.43 (0.41) 0.07 (0.08) 0.287
21 c. 3725+51T>G N/A - Intron 19 0.98 (0.98) 0.02 (0.02) 0.00 (0.00) 0.009
22 c. 3726-47A>G N/A - Intron 19 0.76 (0.74) 0.20 (0.24) 0.04 (0.02) 0.139
23 c.3945+171C>T N/A - Intron 21 0.96 (0.93) 0.00 (0.07) 0.04 (0.00) 0.038
24 c. 3946-48C>A N/A - Intron 21 0.94 (0.91) 0.02 (0.09) 0.04 (0.00) 0.046
25 c. 4383-232T>G rs9855919 - Intron 24 0.43 (0.38) 0.36 (0.47) 0.21 (0.15) 0.387
26 c.4383-177C>T rs10804682 - Intron 24 0.72 (0.74) 0.28 (0.24) 0.00 (0.02) 0.139
27 c. 5208T>C rs2227931 Tyr1736Tyr Exon 30 0.38 (0.32) 0.37 (0.49) 0.25 (0.19) 0.441
28 c. 5288+130G>A rs11916455 - Intron 30 0.44 (0.26) 0.31 (0.48) 0.25 (0.16) 0.403
29 c. 5380+121C>A rs11927681 - Intron 31 0.87 (0.87) 0.13 (0.13) 0.00 (0.00) 0.065
30 c. 5460T>C rs2227932 Tyr1820Tyr Exon 32 0.79 (0.78) 0.19 (0.21) 0.02 (0.01) 0.115
31 c. 5558+119C>T N/A - Intron 32 0.96 (0.92) 0.00 (0.08) 0.04 (0.00) 0.038
32 c. 5739-4dc19+T N/A - Intron 33 0.94 (0.91) 0.02 (0.09) 0.04 (0.00) 0.046
33 c.5868C>T N/A Tyr1956Tyr Exon 34 0.96 (0.93) 0.00 (0.07) 0.04 (0.00) 0.038
34 c. 6394T>G rs28910273 Tyr2132Asp Exon 38 0.98 (0.98) 0.02 (0.02) 0.00 (0.00) 0.009
35 c. 6553-45C>G N/A - Intron 38 0.98 (0.98) 0.02 (0.02) 0.00 (0.00) 0.010
36 c. 6897+88A>G N/A - Intron 40 0 98 (0 98) 0.02 (0.02) 0.00 (0.00) 0.009
37 c. 7041+8G>A N/A - Intron 41 0.98 (0.98) 0.02 (0.02) 0.00 (0.00) 0.009
38 c. 7041+55T>A N/A - Intron 41 0.98 (0.98) 0.02 (0.02) 0.00 (0.00) 0.009
39 c. 7274G>A rs2229032 Arg2425Gln Exon 43 0.75 (0.73) 0.02 (0.25) 0.04 (0.02) 0.147
40 c. 7875A>G rs1802904 Gln2625Gln Exon 47 0.80 (0.77) 0.16 (0.22) 0.04 (0.01) 0.120
41 c. 7932+104T>C rs10935463 - Intron 47 0.39 (0.33) 0.37 (0.49) 0.24 (0.18) 0.422
1According to the nomenclature of the Human Genome Variation Society
2As expected under Hardy-Weinberg equilibrium
N/A: Information not available for this SNP (not reported in dbSNP)
T allele is considered as the common allele according to the reference sequence NM_001184
MAF : Minor Allele FrequencyBMC Cancer 2006, 6:230 http://www.biomedcentral.com/1471-2407/6/230
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tion. When estimating the ATR haplotypes reconstructed
from the 17 SNPs having a MAF ≥ 5% in breast cancer
cases, 24 haplotypes were identified from our data. Of
these, 13 haplotypes exhibited a combined frequency
≥1%, which represent 95% of all haplotypes estimated by
PHASE in cases and controls combined (data not shown).
Thereafter, in order to identify ATR tSNPs useful for well-
powered studies using larger sample sets, genotypes of 17
coding and intronic SNPs showing a MAF ≥5% in healthy
individuals have been used for further haplotype analyses
(Figure 3, Panel A). Genotyping data from controls only
were purposely selected as they could well be more repre-
sentative of the French Canadian population. When only
haplotypes displaying a MAF ≥5% are used, 85% of all
estimated haplotypes are represented by the tSNPs identi-
fied.
The identification of tSNPs was then carried out in two
subsequent steps, firstly by determining haplotype blocks,
followed by identification of tSNP in each LD block.
Based on the algorithm from Gabriel et al. [71], three LD
blocks have been identified in the French Canadians by
the Haploview software (expectation maximisation algo-
rithm) (Figure 3, Panel B). Thereafter, considering haplo-
types having a MAF ≥5%, 8 tSNPs have been identified in
the 3 LD blocks, namely SNPs 2, 5, 12 and 26 found in
block 1, SNPs 30 and 39 in block 2, while block 3 consists
of SNPs 40 and 41. Furthermore, seven tSNPs clustered in
two LD blocks were selected in the ATR gene using the
HapMap data from the CEPH/CEU cohort. It is of interest
to note that three tSNPs have been tagged in both the
French Canadian and the CEPH/CEU sample sets.
Splicing consensus sequence analysis
The possible effect on splicing of all coding or intronic
variants located in a splice junction was assessed using the
SSPNN website and revealed that the intronic variant
c.5739-4del9+T (SNP32) located 4 nucleotides upstream
of exon 34 decreased exon 34 consensus acceptor site
score from 0.94 to 0.31 (Figure 4, Panel A). The presence
of the intronic variant c.5739-4del9+T, located in intron
33, became of interest regarding its possible implication
to generate a new alternative ATR transcript. Acceptor and
Donor splice site sequences in this region are well con-
served between mammalian species as illustrated in Fig-
ure 4. Moreover it should be noted that the in silico
analysis revealed a weak donor splice site score (0.11) for
exon 33 while a putative donor site with a higher splicing
score (0.63) was predicted in exon 33, potentially gener-
ating an alternative exon.
Another rare variant (c. 7041+8G>A) showed a significant
alteration in the splicing score for a donor site, leading to
a score from 0.51 to 0.24 (Figure 4, Panel B). In silico anal-
ysis of the region surrounding the c.7041+8G/A variant
revealed that a putative intronic donor site located 441
nucleotides downstream of the exon 41 could be alterna-
tively used instead of the exon 41 donor site. The WT exon
41 donor site found in other species displays a weak splic-
ing score. The intronic putative donor site located in
intron 41 has a higher splicing score in human (0.90) and
Table 2: ATR sequence variant allele frequencies in different cohorts
French-Canadian families Validation group Finnish families2 Reported in NCBI database
SNP SNP ID1 dbSNP ID n MAF n MAF n Carrier frequency MAF
- C.268C>T N/A 51 0.000 - - 126 0.127 N/A
5* C.632C>T rs2227928 52 0.385 45 0.389 126 0.460 0.425
6 c.946G>A rs28897764 50 0.047 42 0.037 126 0.000 N/A
11 C.1776A>T rs2227930 53 0.415 - - 126 0.508 0.412
12 C.1815T>C rs2227929 53 0.406 - - 126 0.468 0.378
14 c.2290A>G N/A 50 0.010 41 0.000 126 0.000 N/A
16 c.2875G>A rs28910271 48 0.052 46 0.000 126 0.000 0.010
27 c.5208T>C rs2227931 49 0.441 - - 126 0.238 0.263
30 c.5460T>C rs2227932 52 0.115 - - 126 0.262 0.105
32 c. 5739-4del9+T N/A 54 0.046 42 0.012 126 0.000 N/A
34 C.6394T>G rs28910273 54 0.009 44 0.000 126 0.008 0.016
39 c.7274G>A rs2229032 51 0.147 41 0.170 126 0.278 0.109
40 c.7875A>G rs1802904 50 0.120 - - 126 0.270 0.101
1 According to the nomenclature of the Human Genome Variation Society
2 Heikkinen et al. 2005, Breast Cancer Research 7 :R495-R501
N/A: Information not available for this SNP or not reported in dbSNP
- Not genotyped
* T allele is considered as the common allele according to the reference sequence NM_001184
MAF : Minor Allele FrequencyBMC Cancer 2006, 6:230 http://www.biomedcentral.com/1471-2407/6/230
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Table 3: Coding and intronic (MAF>5%) sequence variations and genotype frequencies in familial breast cancer cases and controls
SNP SNP ID1 Series # individual Common homozygote 
No. (expected)2
Heterozygote No. 
(expected)2
Rare homozygote No. 
(expected)2
MAF3 X2 p-value4
2 c.60-51A>T Cases 54 44 (44.3) 10 (9.2) 0 (0.5) 0.093 0.453
Controls 62 49 (47.9) 11 (13.2) 2 (0.9) 0.121 0.192
5* c.632C>T Cases 52 22 (19.8) 20 (24,4) 10 (7.8) 0.385 0.176
Controls 71 26 (29.8) 40 (32.4) 5 (8.8) 0.344 0.048
6 c.946G>A Cases 53 50 (48.1) 1 (4.7) 2 (0.1) 0.047 <0.001
Controls 68 68 (68.0) 0 (0.0) 0 (0.0) 0.000 -
7 c.1326A>G Cases 54 51 (49.1) 1 (4.9) 2(0.0) 0.046 <0.001
Controls 72 68 (68.1) 4 (3.9) 0(0.1) 0.028 0.808
8 c.1488C>T Cases 51 50 (50.0) 1 (1.0) 0 (0.0) 0.010 0.944
Controls 73 73 (73.0) 0 (0.0) 0(0.0) 0.000 -
11 c.1776A>T Cases 53 21 (18.0) 20 (26.0) 12 (9.0) 0.415 0.105
Controls 70 25 (29.6) 41 (31.8) 4 (8.6) 0.350 0.016
12 c.1815T>C Cases 53 21 (18.5) 21 (25.5) 11 (9.0) 0.406 0.194
Controls 71 25 (25.5) 35 (34.1) 11 (11.4) 0.401 0.828
13 c.1950G>A Cases 53 50 (48.2) 1 (4.8) 2(0.0) 0.047 <0.001
Controls 71 68 (68.0) 3 (2.9) 0(0.1) 0.021 0.856
14 c.2290A>G Cases 50 49 (49.0) 1 (1.0) a (0.0) 0.010 0.943
Controls 72 72 (72.0) 0 (0.0) 0 (0.0) 0.000 -
15 c.2634-74T>C Cases 54 21 (18.3) 21 (26.3) 12 (9.4) 0.417 0.142
Controls 51 15 (18.2) 31 (24.6) 5 (8.2) 0.402 0.059
16 c.2875G>A Cases 48 4S (43.2) 1 (4.8) 2(0.0) 0.052 <0.001
Controls 68 64(64.0) 4 (3.9) 0(0.1) 0.028 0.803
18 c.3120G>A Cases 52 49 (47.3) 1 (4.7) 2 (0.0) 0.048 <0.001
Controls 70 66(66.0) 4 (3.9) 0(0.1) 0.028 0.806
20 c.3357+128G>A Cases 54 27 (27.5) 23(22.1) 4(4.4) 0.287 0.765
Controls 64 41 (40.7) 20 (20.7) 3 (2.6) 0.203 0.781
22 c.3726-47A>C Cases 54 41 (40.0) 11 (13.0) 2 (1.0) 0.139 0.275
Controls 65 44(43.2) 18(19.6) 3(2.2) 0.185 0.518
25 c.4383-232T>G Cases 63 33 (19.9) 19 (25.2) 11 (7.9) 0.387 0.013
Controls 65 23 (25.9) 36 (30.3) 6(8.8) 0.369 0.127
26 c.4383-177C>T Cases 54 39(40.0) 15(13.0) 0(1.0) 0.139 0.236
Controls 65 37(37.0) 24 (24.1) 4(3.9) 0.246 0.967
27 c.5208T>C Cases 51 39 (16.3) 19 (25.0) 13 (9.7) 0.441 0.081
Controls 65 23 (23.4) 32 (31.2) 10(10.4) 0.400 0.836
28 c.5288+130G>A Cases 36 16 (12.9) 11 (17.3) 9(5.8) 0.403 0.028
Controls 55 20 (21.7) 29 (25.7) 6(7.6) 0.372 0.344
29 c.5380+121C>A Cases 46 40 (40.2) 6 (5.6) 0(0.2) 0.065 0.636
Controls 62 JO (48.8) 10 (12.4) 2 (0.8) 0.113 0.125
30 c.5460T>C Cases 52 41 (40.1) 10(11.4) 1 (0.5) 0.115 0.676
Controls 72 62 (62.4) 10 (9.3) 0(0.3) 0.069 0.526
32 c.5739-4del9+T Cases 54 51 (49.1) 1 (4.9) 2(0.0) 0.04 <0.001
Controls 63 60 (60.0) 3 (2.9) 0 (0.0) 0.024 0.846
33 c.5868C>T Cases 53 51 (49.3) 0 (3.7) 2 (0.0) 0.038 <0.001
Controls 67 67(67.0) 0 (0.0) 0 (0.0) 0.000 -
34 c.6394T>G Cases 54 53 (52.9) 1 (1.1) 0(0.0) 0.009 0.945
Controls 66 66 (66.0) 0 (0.0) 0 (0.0) 0.000 -
37 c.7041+8G>A Cases 53 52(52.1) 1 (0.9) 0 (0.0) 0.009 0.945
Controls 70 65 (63.2) 3 (6.6) 2(0.2) 0.050 <0.001
39 c.7274G>A Cases 51 38(37.2) 11 (12.8) 2 (1.0) 0.147 0.317
Controls 70 39(40.9) 29 (25.2) 2(3.9) 0.236 0.210
40 c.7875A>G Cases 50 40(38.5) 8 (11.0) 2 (0.5) 0.120 0.086
Controls 63 45 (45.4) 17 (16.1) 1 (1.5) 0.151 0.670
41 c.7932+104T>C Cases 51 20 (17.0) 19 (24.9) 12 (9.1) 0.422 0.009
Controls 53 19 (18.7) 25 (25.6) 9(8.7) 0.406 0.874
1 According to the nomenclature of the Human Genome Variation Society
2 As expected under Hardy-Weinberg equilibrium
3 Minor allele frequency
4 p-value for deviation from Hardy-Weinberg equilibrium (Pearson's chi-square)
* T allele is considered as the common allele according to the reference sequence NM_001184BMC Cancer 2006, 6:230 http://www.biomedcentral.com/1471-2407/6/230
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Pan troglodyte (0.90), while no corresponding sequence
could be identified in other species analyzed.
Assessment of the presence of alternative transcripts
Following direct sequencing of cDNA PCR products in the
region surrounding the c.5739-4del9+T and the
c.7041+8G/A variants, we found a novel alternative splice
mRNA (∆33 splice form) showing a deletion of the last
121 nucleotides at the end of exon 33 (Figure 5, Panel A).
The deletion causes a shift in the open reading frame
(ORF) creating a premature stop codon in exon 34, yield-
ing a putative truncated protein of 1889 amino acids
Table 4: Sequence variants detected in Human ATR and residues found in orthologues
SNP SNP ID* Amino acid 
change
Pan 
troglodytes
Canis 
familiaris
Mus 
musculus
Xenapus 
laevis
Fugu rubribes Strongylocentrotus 
purpuratus
Drosophila 
melanogaste
5** c.632C>T Thr211 Met Thr Thr Met Met Gly - Glu
6 c. 946G>A Va1316Ile Val Val Val Val Val Ser Asp
14 c. 2290A>G Lys764Glu Lys Lys Lys Lys Lys Ser Glu
16 c. 2875G>A Val959Met Met Met Ile Met Ser Thr Phe
34 c. 6394T>G Tyr2132Asp Tyr His Arg Gln Asn Lys Ala
39 c. 7274G>A Arg2425Gln - Arg Gln Lys Lys Glu Thr
* According to the nomenclature of the Human Genome Variation Society
- No corresponding residue in this species
** T allele is considered as the common allele according to the reference sequence NM_001184
Genomic structure of the human ATR gene Figure 1
Genomic structure of the human ATR gene. The sizes of exons and introns are represented by proportionaly sized dark boxes 
and solid lines, respectively. The 5' and 3' untranslated regions are indicated by light boxes in the gene and mRNA structure. 
The GenBank accession number corresponding to the ATR gene contig, the mRNA and the protein are indicated below the 
nucleotide and protein sequence. The domains involved in the ATR protein activity are illustrated in the protein structure. All 
polymorphisms are indicated in open boxes while amino acid nomenclature is also represented.BMC Cancer 2006, 6:230 http://www.biomedcentral.com/1471-2407/6/230
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which lacks the C-terminal part of the FAT domain, the
entire kinase catalytic domain as well as the FATC
domain. Subcloning of PCR products covering this region
confirmed the presence of this ∆33 splice form in the
immortalized lymphoblastoid cell lines from our breast
cancer cases (Figure 6). Analysis through the UCSC
genome website revealed the presence of two human ESTs
corresponding to the ∆33 splice transcript sequence
(BG770191 and CD642306), supporting the presence of
such a transcript in humans. Interestingly this alternative
transcript uses the putative 3' splicing site predicted in
exon 33 described above, which is conserved in most of
the mammalian species analyzed. In order to confirm that
no additional alternative transcripts involving the skip-
ping of exon 34 could be generated due to this c.5739-
4del9+T variant, we used specific primers located on puta-
tive exon 33–35 and ∆33-35 junctions in combination
with upstream and donwstream primers for PCR amplifi-
cation. No such detectable PCR product was observed.
Besides, no EST corresponding to this potential transcript
was found in the UCSC genome website.
No alternative splice transcript has been identified in the
region comprising the c.7041+8G/A variant using stand-
ard procedures such as PCR amplification with external
primers located on exon 38–39, 39–40, 43–44 and 44–45
junctions, followed by subcloning. However, PCR ampli-
fication using a specific primer located on a putative
exon41-intron41 junction or another primer located 441
nucleotides downstream of exon 41 on the putative
Intron41-Exon42 junction identified by in silico analysis
as described above, revealed the presence of such an alter-
native transcript (Figure 5, Panel B). However, this alter-
native transcript is not reported in UCSC database. Since
preliminary expression analyses performed in immortal-
ized cell lines of an c.7041+8G/A heterozygote carrier and
9 wild-type individuals revealed an expression at the limit
of detection (data not shown), no further expression anal-
yses have been performed.
Characterization of ∆33 splice mRNA expression
Further characterization of expression levels of ∆33 splice
form was performed in several normal tissues and cancer
cell lines. As shown in panel A (Figure 6), relative expres-
sion levels of ∆33 splice form are highest in the breast and
ovary, with relative expression levels of approximately
18% and 13% of the wild-type full-length splice form,
while other examined tissues showed similar and lower
expression levels. In breast cancer cell lines, ∆33 splice
form expression ranges from approximately 6% to 11% in
relation to total exon 33 expression (wild-type + ∆33
splice form) and no significant variation is observed
according to estrogen receptor or differentiation status.
ATR wild-type expression levels standardized for 18S RNA
levels are also illustrated in panel B of Figure 6, and show
variable expression across tissue samples and somewhat
slightly higher expression levels in cancer cell lines.
Is the c.5739-4del9+T variant associated with ∆33 splice 
transcripts?
Assessment of association between the c.5739-4del9+T
variant and the expression of the ∆33 splice form was per-
formed using real-time PCR in RNA samples obtained
from lymphoblastoid cell lines of 38 of the screened cases,
which included 35 wild-type individuals, one heterozy-
gote and two homozygotes for the c.5739-4del9+T vari-
ant. As illustrated in Figure 7, the presence of the ∆33
splice transcript was detected in all individuals, including
wild-type individuals, therefore supporting that the
expression of this splice form is not associated with the
presence of the intronic c.5739-4del9+T variant. Further-
more, more interestingly, expression levels do not seem to
correlate with genotype status, as observed in hetero-
zygous and homozygous individuals, and high expression
variability is also observed in wild-type individuals,
whose mean expression level was 2.733 ± 1.806.
Since no evidence suggested that the c.5739-4del9+T var-
iant could be associated with the presence or the expres-
sion of the ∆33 splice form, amplification of several cDNA
fragments covering exons 30–38 using different combina-
tions of primers located on exon-exon junctions (Figure
5) was performed to detect any additional splice form
resulting from the effect of this sequence change on
mRNA splicing. No additional splice mRNA was
observed.
Discussion
Since it is well established that the residual familial risk of
breast cancer, not caused by BRCA1  or  BRCA2  genes,
could be explained by a polygenic or high-risk genes het-
erogeneity model [72,73], we selected individuals affected
with breast cancer without mutations in BRCA1/2 genes
from high-risk families (one individual per family), in
order to increase the power of the study to find genetic
variants involved in breast cancer susceptibility. So far,
several genes have been investigated based on their inter-
action with BRCA1/2 or their involvement in DNA repair
mechanisms. Since BRCA1/2 genes are intimately linked
to genomic stability, other genes involved in this pathway
are very good candidates to be BRCA3, and this is espe-
cially true of ATM and ATR which play a central role in
genome stability maintenance. The ATM gene has been
suspected to be a breast cancer susceptibility locus, due to
the presence of breast cancer in A-T families, particularly
among  ATM  heterozygotes [74]. ATM  mutations have
already been reported to increase breast cancer suscepti-
bility [9,27,75], while some other sequence variants
located in this gene do not seem to be linked to breast can-
cer [24].BMC Cancer 2006, 6:230 http://www.biomedcentral.com/1471-2407/6/230
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Based on the similar roles played by ATM and ATR as sen-
sors of DNA damages, ATR may be considered a putative
candidate gene that could possibly explain a fraction of
the remaining familial breast cancer risk. Association of
ATR germline mutation with breast cancer susceptibility
has been previously analyzed in Finnish 126 families [70],
and no germline mutation was identified in this founder
population. The current study, performed in a French
Canadian cohort, also being a founder population, was
designed to assess the possible involvement of ATR germ-
line deleterious mutations in breast cancer predisposition.
No deleterious germline mutation leading to a premature
termination of the protein were identified in the coding
region. However, 41 sequence variants were identified,
among which 16 were coding variants while 21 were
novel changes. In addition we find it unlikely that neither
of the common missense substitutions located in the FAT
and kinase domains (c.6394T>G and c.7274G>A) have a
significant effect on protein function because: (i) their fre-
quencies are similar in cases and controls, especially for
c.7274G>A whose MAF is greater than 20% in controls
and (ii) these residues are not well conserved in other spe-
cies (Table 4). Indeed, the polymorphisms displaying a
significant deviation from HWE are composed of a group
of 14 uncommon polymorphisms identified in the same
3 breast cancer cases (2 homozygotes and 1 heterozygote),
and therefore this most likely constitutes a single rela-
tively rare allele. It has to be stated that no particular char-
acteristics seem to emerge for the families bearing any of
these rare variants, as both the French Canadian and the
validation families have been recruited on the basis of
high-risk breast cancer families.
Comparison of polymorphism frequencies between our
cohort and the Finnish cohort [70] is not fully informative
since the latter does not distinguish the number of heter-
ozygotes and homozygotes found in their cohort but only
the number of carriers of a given polymorphism. How-
ever, if we also use this method to calculate polymor-
phism frequencies observed in our cohort, only SNP40
displayed a notably lower frequency than that found in
the Finnish cohort. As stated earlier, both studies (Heik-
kinen et al. and the present study) have been designed to
identify  ATR  deleterious germline mutations in breast
cancer cases. No such mutation was found in either study,
therefore ATR is unlikely to play a major role as a high
penetrance gene in breast cancer predisposition. Even
though novel variants have been identified, the possible
involvement of polymorphisms or haplotypes observed
in cases compared to those found in controls would need
a lot more individuals to obtain a significant value of
association to breast cancer susceptibility [76,77]. We
thus sought to identify tSNPs that could be useful to other
studies and populations.
Our pairwise linkage disequilibrium analysis (Figure 2)
did not seem to identify any distinct LD blocks within
ATR. This observation is supported by the fact that SNP1
is in perfect LD with most other SNPs, including the most
distal SNP41, and is also in accordance with what is seen
in the French Canadian founder population which dis-
plays large conserved haplotypes as reported at the BRCA1
locus [49]. However, using the Haploview software, three
distinct LD blocks were identified at the ATR locus when
using SNPs showing a MAF >5% in healthy French Cana-
dian individuals (Figure 3). The breakage of strong LD
seems to be located in the region of exon 31, and between
exon 43 and exon 47.
Based on the same algorithm (Haploview), and using the
SNPs genotyped in HapMap database showing a MAF
higher than 5%, two LD blocks could be identified; the
first block comprising the SNPs located from intron 1 to
exon 43, while the second block included all the remain-
ing SNPs until exon 47. However, it should be noted that
the majority of the SNPs used to determine haplotype
blocks have a MAF higher than 0.4, which represent com-
mon SNPs found in many different populations and
therefore probably exclude the SNPs specifically observed
in our French Canadian founder population.
Pairwise linkage disequilibrium (LD) measures of |D'| for the  41 SNPs identified in our breast cancer cases series Figure 2
Pairwise linkage disequilibrium (LD) measures of |D'| for the 
41 SNPs identified in our breast cancer cases series. All SNPs 
are denoted numerically with reference to Table 1.BMC Cancer 2006, 6:230 http://www.biomedcentral.com/1471-2407/6/230
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Panel A: The Table denotes the frequencies, using PHASE, of haplotypes using SNPs having a MAF higher than 5% estimated in  controls Figure 3
Panel A: The Table denotes the frequencies, using PHASE, of haplotypes using SNPs having a MAF higher than 5% estimated in 
controls. Panel B: Haplotype blocks predicted using SNPs identified in control series showing a MAF higher than 5% (17 SNPs). 
tSNPs identified on a block-by-block basis are denoted with an asterisk (*) above the SNP number. Population haplotype fre-
quencies are displayed on the right of each haplotype combination while the level of recombination is displayed above the con-
nections between two blocks. Thick connections represent haplotypes with frequencies higher than 10% while frequencies 
below 10% are represented by thin lines.BMC Cancer 2006, 6:230 http://www.biomedcentral.com/1471-2407/6/230
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Panel A: Comparative analysis of splicing site sequences in ATR exon 32, 33, ∆33 and 34 flanking exon-intron junctions as well  as prediction of impact of SNP32 (c.5739-4del9+T) on exon 34 acceptor site Figure 4
Panel A: Comparative analysis of splicing site sequences in ATR exon 32, 33, ∆33 and 34 flanking exon-intron junctions as well 
as prediction of impact of SNP32 (c.5739-4del9+T) on exon 34 acceptor site. Panel B: Comparative analysis of splicing site 
sequences in ATR exon 41, ins∆Int41 and exon 42 flanking exon-intron junctions as well as prediction of impact of SNP37 
(c.7041+8G/A) on exon 41 donor site. Splice Site Prediction Program using Neural Network (SSPNN) score values are indi-
cated in parenthesis below each sequence. Exonic nucleotides are represented by uppercase letters while intronic sequences 
are represented by lowercase letters. m = c or a, r = a or g, y = t or c and n = any nucleotide. N.A. = value not available. Con-
sensus sequences of acceptor and donor sites were described by Burge et al. 1999 [84].BMC Cancer 2006, 6:230 http://www.biomedcentral.com/1471-2407/6/230
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Panel A: Alternative splicing of ATR ∆33 exon Figure 5
Panel A: Alternative splicing of ATR ∆33 exon. Schematic representation of the design used to assess the existence of mRNA 
splice transcript encompassing exons 33 and 34 in immortalized cell lines of individuals affected with breast cancer. The puta-
tive truncated ATR protein of 1889 amino acids lacks the functional domains identified in the wild type ATR protein. Panel B: 
Alternative splicing of ATR ins∆Int41 exon. Schematic representation of the design used to assess the existence of mRNA splice 
transcript encompassing exons 41 and 42 in immortalized cell lines of individuals affected with breast cancer. The putative trun-
cated ATR protein of 2350 amino acids lacks a part of the kinase domains identified in the wild type ATR protein.BMC Cancer 2006, 6:230 http://www.biomedcentral.com/1471-2407/6/230
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Expression levels of ATR ∆33 splice form in cell lines and human tissues as measured by quantitative real-time PCR experi- ments Figure 6
Expression levels of ATR ∆33 splice form in cell lines and human tissues as measured by quantitative real-time PCR experi-
ments. Panel A. Relative expression levels of ∆33 splice form were calculated as ∆33 splice form/(∆33 splice form + wild-type 
allele) in various human tissues and cell lines. Panel B. Standardized expression levels of WT exon 33 were calculated as WT 
exon 33/(∆33 splice form + wild-type allele) in various human tissues and cell lines.BMC Cancer 2006, 6:230 http://www.biomedcentral.com/1471-2407/6/230
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We were able to demonstrate that 8 tSNPs are sufficient to
represent the majority of ATR haplotypes in our French
Canadian individuals, which will greatly facilitate subse-
quent studies. Our results of 8 tSNPs at the ATR locus in
our population is consistent with previously reported
number of tSNPs required at other gene loci in other pop-
ulations [78,79]. We can therefore be quite confident that
these tSNPs will be useful in subsequent analyses. Moreo-
ver, out of 72 SNPs genotyped in the HapMap database
(HapMap data rel#20 on NCBI B35 assembly, dbSNP
b125) at the ATR locus, only 40 displayed a MAF >5%.
Among them, 7 tSNPs were identified, 3 of which have
been identified as tSNPs in our analyses (rs10804682,
rs2229032, rs1802904). Of the remaining four tSNPs
identified in HapMap database (rs11920625, rs9856772,
rs6805118 and rs9816736), three have not been geno-
typed in our cohort as they were located in intronic
regions (>150–200 bp) and one (rs11920625) was not
observed in our individuals.
Sequence analysis of exon 34 flanking intronic sequences
revealed a deletion of 9 nucleotides + insertion T (c.5739-
4del9+T), which is located 4 nucleotides upstream of this
exon. In silico analysis showed that this deletion decreased
the exon 34 acceptor site splicing score from 0.94 to 0.31,
which suggests potential splicing alteration in this region.
Surprisingly, sequence analysis of this cDNA region in our
immortalized cell lines revealed a deletion of the last 121
nucleotides of exon 33 instead of a skipping of exon 34
(or a portion of exon 34), as expected. This deletion of
121 nucleotides alters the ORF and results in a putative
truncated protein of 1889 amino acids. Although interest-
ing, this deletion is observed at similar levels in all tested
individuals and is therefore unlikely related to the c.5739-
4del9+T polymorphism. This ∆33 splice form may be
explained by the weak wild-type donor site score of exon
33 (0.11) and the presence of an additional donor site
located within exon 33, which exhibits a score of 0.63. No
splice form involving the skipping of exon 34 has been
identified when using specific primers located on the
putative ∆33-35 or 33–35 exon junctions.
Splicing score analyses of exon 41 flanking intronic
sequences were also analyzed since c.7041+8G/A could
potentially affect the splicing in this region. While the
exon 41 donor splice site showed a relative low splicing
score in all species, the putative intronic donor site (splic-
ing score of 0.90) located 441 nucleotides downstream of
exon 41 became of interest, given its potential effect on
splicing in this region (Figure 4). The ins∆Int41 splice
form could not be detected using standard procedures.
However, this splice form has been amplified and sub-
cloned by using specific primers located on this putative
exon junction, demonstrating its very low mRNA expres-
sion (at the limit of detection). Due to this low expres-
sion, it was impossible to conclude whether or not this
ins∆Int41 splice form is associated with the c.7041+8G/A
variant.
The ratio of ∆33 splice form/WT form being a potentially
important factor regarding DNA repair and other related
functions in genome stability, we performed QRT-PCR to
estimate the relative abundance of WT and ∆33 splice
form mRNAs, using TAQMAN probes to allow discrimi-
nation between both forms. No correlation was found
between the presence of c.5739-4del9+T in either the het-
erozygous or homozygous state and the expression levels
of the ∆33 splice form. However, it is very interesting that
significant relative expression of the ∆33 splice mRNA is
observed in breast and ovarian tissues, as well as in MCF7
and HaCat (human skin keratinocytes) cells (Figure 6A),
especially since expression levels of the WT ATR form in
these tissues (Figure 6B) seem to be relatively similar to
other tissues and cell lines. The ratio of expression levels
between both mRNAs could therefore be of primary issue
regarding the effect of the balance of these transcript levels
on cell integrity in different human tissues. However it
should be noted that only one sample per tissue was ana-
lyzed, which by no means represents a mean expression in
these tissues or cell lines. While alternative splicing within
the non-catalytic domain of ATR mRNA transcript causing
skipping of exon 6 had already been observed [80], in
2003 O'Driscoll and coll. [81] identified a founder muta-
tion (2101A→G) in ATR that affects exon 9 splicing in two
related Pakistani families affected with Seckel syndrome.
This study also shows an impaired response to DNA dam-
age in a cell line from an affected parent who carried the
Expression levels of ∆33 splice form in homozygote, hetero- zygote and wild-type individuals for c.5739-4del9+T variant  as measured by quantitative real-time PCR experiments Figure 7
Expression levels of ∆33 splice form in homozygote, hetero-
zygote and wild-type individuals for c.5739-4del9+T variant 
as measured by quantitative real-time PCR experiments. For 
the 35 wild type individuals, the confidence interval is repre-
sented by an open box with the median indicated.BMC Cancer 2006, 6:230 http://www.biomedcentral.com/1471-2407/6/230
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mutation. Further characterization of ATR-Seckel cells
showed impaired phosphorylation of ATR-dependent
substrates, impaired G2/M checkpoint arrest and super-
numery centrosomes in mitotic cells, clearly demonstrat-
ing a role for ATR in the maintenance of centrosome
stability [82]. More recently, two other splicing alterations
of ATR have been reported in clinical samples with pyot-
horax-associated lymphoma [83].
Conclusion
No deleterious germline mutations have been identified
in French Canadian breast cancer cases. However, we have
conducted the first detailed haplotype tagging analysis of
the ATR gene within control individuals from the French
Canadian population. The data presented here clearly
identified 8 ATR tSNPs, which will be useful for other
large-scale association studies. We did not find any germ-
line mutations in the ATR gene potentially involved in
breast cancer predisposition. However, given that differ-
ent splicing alterations of ATR have been associated with
impaired response to DNA damage, the notably signifi-
cant expression of the novel ∆33 splice form observed in
breast and ovarian tissues could have a potential effect on
DNA repair mechanisms in these cells, although exhaus-
tive analyses should be required to verify this hypothesis.
Further analyses in other populations and larger cohorts
will be required to define the possible association of ATR
gene polymorphisms with breast cancer susceptibility.
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